Developer docs
API playgroundTry for free, no card

Search company profiles

Nexsen

Full company profile

uuid003ruzt

Namestring
Nexsen
Legal namestring
Nexsen Limited
Websiteurl
nexsen.bio
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Nexsen (ASX: NXN) is a clinical-stage nano-biotechnology company founded in 2021 and dual-headquartered in Sydney, Australia (corporate) and Melbourne (R&D at the Royal Melbourne Institute of Technology), with an APAC commercial hub in Hong Kong. The company develops rapid, point-of-care diagnostic sensors built on a proprietary platform that combines ultra-bright nanoparticle chemistry with a modular lateral-flow architecture, enabling multiplexed biomarker detection in minutes at the bedside rather than days in a central laboratory. Its lead product, the GBS Rapid Sensor, targets Group B Streptococcus colonisation in obstetric settings to reduce neonatal sepsis risk, with clinical trials scheduled to commence in Q4 2025. The pipeline reported beyond GBS spans infectious disease, lung cancer, and organ transplant rejection, all served by the same core platform plus an AI-assisted biomarker discovery layer used to screen candidate nano-formulations for diagnostic sensitivity.

The company intends to monetise through device-plus-consumable sales into hospital and clinical laboratory channels, with parallel regulatory pathways pursued in the US (FDA De Novo via regulatory partner MCRA), EU (CE-IVD), and APAC jurisdictions. Distribution and clinical validation are anchored by named partnerships with GHK Hospital, Northern Health, and Universiti Malaya, while R&D capability is supplied by an equity-linked collaboration with RMIT that hosts more than 40 researchers under the direction of Chief Innovation Officer Professor Vipul Bansal. To date, the company has not generated product revenue and is funded primarily through ASX equity issuance and approximately A$11.9 million in cumulative non-dilutive government grants (A$3M Australian, A$1.2M Hong Kong, A$7.7M CRC-P).

Short descriptiontext

Nexsen is a clinical-stage nano-biotechnology company developing rapid, point-of-care diagnostic sensors built on proprietary ultra-bright nanoparticle and modular lateral-flow technology, with its lead GBS Rapid Sensor targeting obstetric Group B Streptococcus detection globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, nanobiotechnology platform, rapid biosensing tests, lateral flow diagnostics, nanoparticle biomarker sensors
Industry3 codes
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Nanotechnology541713
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Point-of-Care Diagnostics
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Device Sales
TypeHardware Sales
Description

Nexsen generates revenue through the sale of rapid point-of-care diagnostic devices and sensors. The company is in clinical stage with first product (GBS Rapid Sensor) commencing clinical trials in Q4 2025 and targeting regulatory submissions in CY 2026. Revenue will come from hospital adoption, clinical laboratories, and healthcare providers across human health, agriculture, and biosecurity sectors.

nexsen.bio
2Testing/Reagent Sales
TypeHardware Sales
Description

Ongoing revenue from consumable test strips and reagents used with the diagnostic platform. The GBS Rapid Sensor uses a vaginal-rectal swab with results visible on a strip similar to pregnancy or COVID tests, implying recurring consumable revenue.

tipranks.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nexsen develops and sells a modular nano-biotechnology biosensing platform that combines ultra-bright nanoparticles, high-affinity biomarkers, and lateral flow architecture to deliver lab-quality point-of-care diagnostics in a low-cost, paper-based format. The platform powers a multi-product pipeline including the GBS Rapid Sensor (lead product), chronic kidney disease and acute kidney injury tests, a bovine mastitis diagnostic, and biosecurity pathogen tests. First product is in clinical trials (Q4 2025) targeting commercialization in CY 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • GBS affects 1 in 4 pregnant women and is a leading cause of newborn infections
+4 more records
Product overview1 text field

Nexsen is a clinical-stage nano-biotechnology company that has developed a modular biosensing platform combining ultra-bright nanoparticles, high-affinity biomarkers, and modular lateral flow architecture to deliver lab-quality diagnostics in a low-cost, user-friendly format. The platform powers a multi-product pipeline spanning human health, agriculture, and biosecurity. The lead product is the GBS Rapid Sensor (rapid Group B Streptococcus diagnostic), complemented by Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) diagnostics in human health, a Bovine Mastitis diagnostic for agriculture, and Biosecurity Pathogen Tests for frontline detection. The platform is developed in partnership with RMIT University's Sir Ian Potter NanoBiosensing Facility and incorporates AI biomarker discovery to accelerate target selection and test performance.

Product and service3 records
1GBS Rapid Sensor
CategoryRapid point-of-care diagnostic
Description

A breakthrough point-of-care rapid diagnostic for Group B Streptococcus using a vaginal-rectal swab that delivers lab-level results in minutes via a pregnancy-test-style strip, targeting the 1 in 4 pregnant women who carry GBS to enable real-time testing at labour.

2Chronic Kidney Disease (CKD) Test
CategoryRenal health diagnostic
Description

A paper-based diagnostic for chronic kidney disease designed for early detection and routine monitoring in clinics, hospitals, and homes, with multi-biomarker capability to identify root causes including diabetes, hypertension, inflammation, and infection.

3Bovine Mastitis Diagnostic
CategoryAnimal health diagnostic
Description

A low-cost, field-deployable on-farm test for bovine mastitis that requires no refrigeration and returns results in minutes to reduce losses, improve treatment decisions, and support sustainable dairy operations.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1GHK Hospital Limited (Gleneagles Hospital Hong Kong)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

Binding term sheet with GHK Hospital Limited, operator of the 500-bed Gleneagles Hospital Hong Kong and part of IHH Healthcare's global network, to clinically validate and commercialize Nexsen's rapid point-of-care diagnostic platform. The collaboration covers clinical validation, real-world data generation, pricing and reimbursement assessments, joint education and training, and creates scope for joint R&D and co-development of new tests targeting Group B Streptococcus and Kidney Function. This partnership reinforces Nexsen's Asia-Pacific strategy and may accelerate its pathway from product development to hospital adoption.

tipranks.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-04
Description

Formalized partnership to establish a joint research facility for food safety diagnostics at Universiti Malaya's Innovative Medical Devices Centre of Excellence. Under the co-funded agreement, Universiti Malaya contributes 50% of establishment costs, granting Nexsen entry into the Malaysian market alongside existing Hong Kong operations. The facility's first project focuses on developing a rapid dual-sensor biosensor to detect E. coli and Salmonella simultaneously, addressing a critical gap identified by the Malaysian Ministry of Health, with the goal of bringing the product to market within 24 months.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-11-06
Description

Nexsen partnered with MCRA to accelerate its U.S. market entry for GBS Rapid Sensor and Kidney Function Diagnostics. MCRA will advise on FDA regulatory pathways and market access, with the first FDA interaction expected in early 2026. This partnership supports Nexsen's regulatory strategy for entering the US diagnostics market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nexsen's platform was developed at the Sir Ian Potter Nano-Biosensing Facility at RMIT University - Australia's most advanced centre for diagnostics innovation. RMIT's equity partnership in Nexsen marks the first company to receive equity investment from RMIT University - a landmark collaboration between academia and industry. The facility brings together over 40 experts in bio-sensing, nanomaterials, and AI to translate breakthrough science into real-world solutions. Professor Vipul Bansal serves as Chief Innovation Officer and Advisory Board Chair, directing the research facility.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Northern Health is conducting clinical trials for the GBS Rapid Sensor commencing Q4 CY 2025, supported by a $7.7 million CRC-P grant including $3 million in Australian Government funding. Northern Health's Chief Medical Officer, Assoc. Prof. Prahlad Ho, serves on Nexsen's Advisory Board. The trials represent the first commercial product path toward regulatory approval.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Nexsen recommends GBS Aware as a trusted resource and advocacy organisation for parents, carers, and clinicians seeking more information about Group B Streptococcus. This represents an educational content partnership to support patient and clinician awareness.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Major women's health diagnostics company with established Group B Streptococcus (GBS) testing products. Directly comparable on lead indication (GBS) and broader molecular/rapid diagnostics portfolio serving hospitals and clinical labs globally.

TypeDirect peer
Description

ASX-listed rapid diagnostic platform company developing user-friendly point-of-care test devices. Closely comparable profile: Australian-listed, pre-commercial or early-commercial diagnostics, similar size and stage, with analogous GTM strategy targeting infectious disease and consumer health channels.

TypeDirect peer
Description

UK-listed point-of-care diagnostics company producing rapid test devices for clinical and industrial markets including infectious disease, women's health, and animal health. Closely comparable business model and product format to Nexsen's lateral flow platform.

TypeBroad incumbent
Description

Global medical technology company with BD Veritor rapid diagnostic systems and extensive microbiology/lab diagnostics portfolio. Broad incumbent serving similar hospital and clinical channels with established regulatory and commercial infrastructure.

TypeDirect peer
Description

Specialized rapid diagnostics company with broad lateral flow and immunoassay product lines spanning infectious disease, women's health, and specialty diagnostics. Direct competitor in point-of-care rapid test formats serving similar hospital and clinical channels.

6Abbott Diagnostics
TypeBroad incumbent
Description

Global diagnostics leader with extensive rapid diagnostic product lines including Binax and Panbio lateral flow tests, plus point-of-care platforms. Broad incumbent offering overlapping capabilities across all Nexsen target indications as part of a much larger diversified portfolio.

TypeEmerging player
Description

US-based developer of rapid diagnostic tests including at-home and point-of-care formats using novel detection chemistries. Comparable as an emerging player pursuing decentralized diagnostics with overlapping product strategy in user-friendly rapid test formats.

TypeBroad incumbent
Description

Global in vitro diagnostics company with strong microbiology and immunoassay portfolios, including industrial and clinical microbiology testing relevant to Nexsen's biosecurity and food safety applications. Comparable as a broader diagnostics incumbent with relevant overlap on bacterial detection.

TypeEmerging player
Description

Australian digital diagnostics company developing connected rapid test platforms for infectious disease. Comparable as a fellow Australian diagnostics innovator with overlapping point-of-care product strategy and similar regulatory pathway challenges.

10NOW Foods (Animal Health Diagnostics) - IDEXX reference
TypeBroad incumbent
Description

Global leader in veterinary diagnostics with extensive livestock and dairy testing products including mastitis detection. Relevant comparable for Nexsen's bovine mastitis diagnostic given overlapping customer base (dairy producers, veterinarians) and parallel product format.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nexsen

Point-of-Care Diagnosticsnexsen.bio

Nexsen is a clinical-stage nano-biotechnology company developing rapid, point-of-care diagnostic sensors built on proprietary ultra-bright nanoparticle and modular lateral-flow technology, with its lead GBS Rapid Sensor targeting obstetric Group B Streptococcus detection globally.

What Nexsen does

Nexsen (ASX: NXN) is a clinical-stage nano-biotechnology company founded in 2021 and dual-headquartered in Sydney, Australia (corporate) and Melbourne (R&D at the Royal Melbourne Institute of Technology), with an APAC commercial hub in Hong Kong. The company develops rapid, point-of-care diagnostic sensors built on a proprietary platform that combines ultra-bright nanoparticle chemistry with a modular lateral-flow architecture, enabling multiplexed biomarker detection in minutes at the bedside rather than days in a central laboratory. Its lead product, the GBS Rapid Sensor, targets Group B Streptococcus colonisation in obstetric settings to reduce neonatal sepsis risk, with clinical trials scheduled to commence in Q4 2025. The pipeline reported beyond GBS spans infectious disease, lung cancer, and organ transplant rejection, all served by the same core platform plus an AI-assisted biomarker discovery layer used to screen candidate nano-formulations for diagnostic sensitivity.

The company intends to monetise through device-plus-consumable sales into hospital and clinical laboratory channels, with parallel regulatory pathways pursued in the US (FDA De Novo via regulatory partner MCRA), EU (CE-IVD), and APAC jurisdictions. Distribution and clinical validation are anchored by named partnerships with GHK Hospital, Northern Health, and Universiti Malaya, while R&D capability is supplied by an equity-linked collaboration with RMIT that hosts more than 40 researchers under the direction of Chief Innovation Officer Professor Vipul Bansal. To date, the company has not generated product revenue and is funded primarily through ASX equity issuance and approximately A$11.9 million in cumulative non-dilutive government grants (A$3M Australian, A$1.2M Hong Kong, A$7.7M CRC-P).

Nexsen firmographics

Firmographics
Name
Nexsen
Legal name
Nexsen Limited
Website
https://nexsen.bio
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Nexsen is a clinical-stage nano-biotechnology company developing rapid, point-of-care diagnostic sensors built on proprietary ultra-bright nanoparticle and modular lateral-flow technology, with its lead GBS Rapid Sensor targeting obstetric Group B Streptococcus detection globally.
Ownership category
akta.pro rank

Nexsen industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical and Medical Instrument Manufacturing (339112)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Point-of-care diagnostics
  • Nanobiotechnology platform
  • Rapid biosensing tests
  • Lateral flow diagnostics
  • Nanoparticle biomarker sensors

Where Nexsen is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Nexsen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Diagnostic Device Sales: Nexsen generates revenue through the sale of rapid point-of-care diagnostic devices and sensors. The company is in clinical stage with first product (GBS Rapid Sensor) commencing clinical trials in Q4 2025 and targeting regulatory submissions in CY 2026. Revenue will come from hospital adoption, clinical laboratories, and healthcare providers across human health, agriculture, and biosecurity sectors.
  2. Testing/Reagent Sales: Ongoing revenue from consumable test strips and reagents used with the diagnostic platform. The GBS Rapid Sensor uses a vaginal-rectal swab with results visible on a strip similar to pregnancy or COVID tests, implying recurring consumable revenue.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Nexsen product offering

Product offering

Core offering

Nexsen develops and sells a modular nano-biotechnology biosensing platform that combines ultra-bright nanoparticles, high-affinity biomarkers, and lateral flow architecture to deliver lab-quality point-of-care diagnostics in a low-cost, paper-based format. The platform powers a multi-product pipeline including the GBS Rapid Sensor (lead product), chronic kidney disease and acute kidney injury tests, a bovine mastitis diagnostic, and biosecurity pathogen tests. First product is in clinical trials (Q4 2025) targeting commercialization in CY 2026.

Product overview

Nexsen is a clinical-stage nano-biotechnology company that has developed a modular biosensing platform combining ultra-bright nanoparticles, high-affinity biomarkers, and modular lateral flow architecture to deliver lab-quality diagnostics in a low-cost, user-friendly format. The platform powers a multi-product pipeline spanning human health, agriculture, and biosecurity. The lead product is the GBS Rapid Sensor (rapid Group B Streptococcus diagnostic), complemented by Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) diagnostics in human health, a Bovine Mastitis diagnostic for agriculture, and Biosecurity Pathogen Tests for frontline detection. The platform is developed in partnership with RMIT University's Sir Ian Potter NanoBiosensing Facility and incorporates AI biomarker discovery to accelerate target selection and test performance.

Differentiator

Problem solved

Functional benefit

Products and services

  • GBS Rapid Sensor A breakthrough point-of-care rapid diagnostic for Group B Streptococcus using a vaginal-rectal swab that delivers lab-level results in minutes via a pregnancy-test-style strip, targeting the 1 in 4 pregnant women who carry GBS to enable real-time testing at labour.
  • Chronic Kidney Disease (CKD) Test A paper-based diagnostic for chronic kidney disease designed for early detection and routine monitoring in clinics, hospitals, and homes, with multi-biomarker capability to identify root causes including diabetes, hypertension, inflammation, and infection.
  • Bovine Mastitis Diagnostic A low-cost, field-deployable on-farm test for bovine mastitis that requires no refrigeration and returns results in minutes to reduce losses, improve treatment decisions, and support sustainable dairy operations.

Quantifiable outcome

  • GBS affects 1 in 4 pregnant women and is a leading cause of newborn infections
  • +4 more outcomes

Companies that use Nexsen

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Nexsen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Nexsen partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • GHK Hospital Limited (Gleneagles Hospital Hong Kong)coreStrategic or Co-development Partner · 12 May 2026Binding term sheet with GHK Hospital Limited, operator of the 500-bed Gleneagles Hospital Hong Kong and part of IHH Healthcare's global network, to clinically validate and commercialize Nexsen's rapid point-of-care diagnostic platform. The collaboration covers clinical validation, real-world data generation, pricing and reimbursement assessments, joint education and training, and creates scope for joint R&D and co-development of new tests targeting Group B Streptococcus and Kidney Function. This partnership reinforces Nexsen's Asia-Pacific strategy and may accelerate its pathway from product development to hospital adoption.
  • Universiti MalayacoreStrategic or Co-development Partner · 4 May 2026Formalized partnership to establish a joint research facility for food safety diagnostics at Universiti Malaya's Innovative Medical Devices Centre of Excellence. Under the co-funded agreement, Universiti Malaya contributes 50% of establishment costs, granting Nexsen entry into the Malaysian market alongside existing Hong Kong operations. The facility's first project focuses on developing a rapid dual-sensor biosensor to detect E. coli and Salmonella simultaneously, addressing a critical gap identified by the Malaysian Ministry of Health, with the goal of bringing the product to market within 24 months.
  • MCRA (Matrical, LLC)coreImplementation/ SI/ Consulting Partner · 6 November 2025Nexsen partnered with MCRA to accelerate its U.S. market entry for GBS Rapid Sensor and Kidney Function Diagnostics. MCRA will advise on FDA regulatory pathways and market access, with the first FDA interaction expected in early 2026. This partnership supports Nexsen's regulatory strategy for entering the US diagnostics market.
  • RMIT University (Sir Ian Potter NanoBiosensing Facility)coreStrategic or Co-development PartnerNexsen's platform was developed at the Sir Ian Potter Nano-Biosensing Facility at RMIT University - Australia's most advanced centre for diagnostics innovation. RMIT's equity partnership in Nexsen marks the first company to receive equity investment from RMIT University - a landmark collaboration between academia and industry. The facility brings together over 40 experts in bio-sensing, nanomaterials, and AI to translate breakthrough science into real-world solutions. Professor Vipul Bansal serves as Chief Innovation Officer and Advisory Board Chair, directing the research facility.
  • Northern HealthcoreStrategic or Co-development PartnerNorthern Health is conducting clinical trials for the GBS Rapid Sensor commencing Q4 CY 2025, supported by a $7.7 million CRC-P grant including $3 million in Australian Government funding. Northern Health's Chief Medical Officer, Assoc. Prof. Prahlad Ho, serves on Nexsen's Advisory Board. The trials represent the first commercial product path toward regulatory approval.
  • GBS AwareminorGTM or Marketing PartnerNexsen recommends GBS Aware as a trusted resource and advocacy organisation for parents, carers, and clinicians seeking more information about Group B Streptococcus. This represents an educational content partnership to support patient and clinician awareness.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Nexsen competitors and assessment

Company assessment

Direct peers

  • Hologic: Major women's health diagnostics company with established Group B Streptococcus (GBS) testing products. Directly comparable on lead indication (GBS) and broader molecular/rapid diagnostics portfolio serving hospitals and clinical labs globally.
  • Atomo Diagnostics: ASX-listed rapid diagnostic platform company developing user-friendly point-of-care test devices. Closely comparable profile: Australian-listed, pre-commercial or early-commercial diagnostics, similar size and stage, with analogous GTM strategy targeting infectious disease and consumer health channels.
  • EKF Diagnostics: UK-listed point-of-care diagnostics company producing rapid test devices for clinical and industrial markets including infectious disease, women's health, and animal health. Closely comparable business model and product format to Nexsen's lateral flow platform.
  • QuidelOrtho: Specialized rapid diagnostics company with broad lateral flow and immunoassay product lines spanning infectious disease, women's health, and specialty diagnostics. Direct competitor in point-of-care rapid test formats serving similar hospital and clinical channels.

Broad incumbents

  • Becton Dickinson (BD): Global medical technology company with BD Veritor rapid diagnostic systems and extensive microbiology/lab diagnostics portfolio. Broad incumbent serving similar hospital and clinical channels with established regulatory and commercial infrastructure.
  • Abbott Diagnostics: Global diagnostics leader with extensive rapid diagnostic product lines including Binax and Panbio lateral flow tests, plus point-of-care platforms. Broad incumbent offering overlapping capabilities across all Nexsen target indications as part of a much larger diversified portfolio.
  • bioMérieux: Global in vitro diagnostics company with strong microbiology and immunoassay portfolios, including industrial and clinical microbiology testing relevant to Nexsen's biosecurity and food safety applications. Comparable as a broader diagnostics incumbent with relevant overlap on bacterial detection.
  • NOW Foods (Animal Health Diagnostics) - IDEXX reference: Global leader in veterinary diagnostics with extensive livestock and dairy testing products including mastitis detection. Relevant comparable for Nexsen's bovine mastitis diagnostic given overlapping customer base (dairy producers, veterinarians) and parallel product format.

Emerging players

  • NOWDiagnostics: US-based developer of rapid diagnostic tests including at-home and point-of-care formats using novel detection chemistries. Comparable as an emerging player pursuing decentralized diagnostics with overlapping product strategy in user-friendly rapid test formats.
  • Ellume: Australian digital diagnostics company developing connected rapid test platforms for infectious disease. Comparable as a fellow Australian diagnostics innovator with overlapping point-of-care product strategy and similar regulatory pathway challenges.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nexsen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nexsen leadership team

Management profile

Number of profiles

Profiles13 records

Nexsen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nexsen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nexsen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexsen

What does Nexsen do?

Nexsen develops and sells a modular nano-biotechnology biosensing platform that combines ultra-bright nanoparticles, high-affinity biomarkers, and lateral flow architecture to deliver lab-quality point-of-care diagnostics in a low-cost, paper-based format. The platform powers a multi-product pipeline including the GBS Rapid Sensor (lead product), chronic kidney disease and acute kidney injury tests, a bovine mastitis diagnostic, and biosecurity pathogen tests. First product is in clinical trials (Q4 2025) targeting commercialization in CY 2026.

Is Nexsen a public or private company?

Nexsen is a public company. It is classified as public and is currently operating.

When was Nexsen founded?

Nexsen was founded in 2021. It employs 1 to 10 people.

Where is Nexsen based?

Nexsen is headquartered in Melbourne, Australia, in the Oceania region.

How does Nexsen make money?

Two revenue lines are on record. Diagnostic Device Sales are the primary driver. The others are testing/Reagent Sales.

Who are Nexsen's main competitors?

Direct peers on record are Hologic, Atomo Diagnostics, EKF Diagnostics and QuidelOrtho. Broad incumbents are Becton Dickinson (BD), Abbott Diagnostics, bioMérieux and NOW Foods (Animal Health Diagnostics) - IDEXX reference. Emerging players are NOWDiagnostics and Ellume.

Does Nexsen have an API?

No public API is recorded for Nexsen.

What industry is Nexsen in?

Nexsen's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 541713 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestNexsen Ltd-global healthcare CEO joins Nexsen advisory boardNexsen Ltd has announced that its chief executive officer has joined the company's advisory board, a move that underscores the organization's commitment to strengthening its strategic governance structure. The advisory board provides guidance on key business decisions, long-term planning, market opportunities, risk management, and innovation strategies in the evolving healthcare sector. The company has not disclosed further details about the board's composition or specific responsibilities, though the development reflects a broader trend among healthcare firms to enhance internal oversight and decision-making transparency.Small CapsNexsen Secures First Asian Hospital Partner for Diagnostic CommercialisationNexsen has signed a binding term sheet with GHK Hospital in Hong Kong to validate and commercialise rapid point-of-care diagnostics across North Asia. The collaboration aims to establish a framework for clinical validation, real-world evidence, and commercialisation support for diagnostics targeting Group B Streptococcus and Kidney Function.TipranksNexsen Strikes Strategic Hong Kong Hospital Deal to Advance Point-of-Care DiagnosticsNexsen Limited has signed a binding term sheet with GHK Hospital Limited, operator of the 500-bed Gleneagles Hospital Hong Kong and part of IHH Healthcare's global network, to clinically validate and commercialize Nexsen's rapid point-of-care diagnostic platform. The collaboration covers clinical validation, real-world data generation, pricing and reimbursement assessments, joint education and training, and creates scope for joint R&D and co-development of new tests. This partnership reinforces Nexsen's Asia-Pacific strategy and may accelerate its pathway from product development to hospital adoption.GrafaNexsen and Universiti Malaya launch food safety hubAustralian medical technology company Nexsen (ASX:NXN) formalized a partnership with Universiti Malaya to establish a joint research facility for food safety diagnostics at UM's Innovative Medical Devices Centre of Excellence. Under the co-funded agreement, Universiti Malaya will contribute 50% of establishment costs, granting Nexsen entry into the Malaysian market alongside its existing Hong Kong operations. The facility's first project focuses on developing a rapid dual-sensor biosensor to detect E. coli and Salmonella simultaneously, addressing a critical gap identified by the Malaysian Ministry of Health, with the goal of bringing the product to market within 24 months.Small CapsNexsen Awarded $1.2m Grant to Advance Strepsure Point-Of-Care Diagnostic in Asia-Pacific MarketsNexsen's Hong Kong subsidiary has been awarded a $1.2 million government grant to advance its StrepSure rapid point-of-care diagnostic for Group B streptococcus (GBS) in maternal health, funding clinical validation through Hong Kong's hospital network and establishing local manufacturing capability. The grant supports Nexsen's strategy to position Hong Kong as a manufacturing and distribution hub for the Asia-Pacific region, bringing the device closer to commercial readiness. GBS is a leading cause of serious neonatal injury or death, affecting approximately one-in-five pregnant women globally, with the device aimed at enabling timely identification during labour.Mirage NewsNexsen Limited Successfully Lists On ASX Following $8 Million Initial Public OfferingNexsen Limited listed on the Australian Securities Exchange on 14 October 2025 following a successful $8 million IPO, becoming the first ASX-listed nano-biotechnology company focused on next-generation point-of-care diagnostics. The capital raised will fund development and commercialisation of the company's proprietary biosensing platform, with an initial focus on its flagship GBS Rapid Sensor for detecting Group B Streptococcus in expectant mothers. The company has secured $7.7 million in Australian Government CRC-P grant funding and is collaborating with RMIT University's Sir Ian Potter NanoBioSensing Facility, with clinical trials for the GBS Rapid Sensor planned for Q4 2025.NexsenNexsen sucessfully lists on ASXNexsen Limited successfully listed on the Australian Securities Exchange on October 14, 2025, completing an $8 million capital raising to fund development of its point-of-care diagnostic platform. The nano-biotechnology company, headquartered at RMIT University's Sir Ian Potter Nanobiosensing Facility in Melbourne, is developing rapid diagnostics including the GBS Rapid Sensor for detecting Group B Streptococcus in expectant mothers, along with kidney disease diagnostics and agricultural pathogen tests. The IPO was managed by Alpine Capital, with RMIT University as a research partner and shareholder in the company.